Compounded GLP-1s Are Being Banned — What California Patients Need to Know Right Now

If you’ve been getting semaglutide or tirzepatide through a compounding pharmacy — whether through a telehealth platform, a med spa, or a direct-to-consumer online service — you need to read this carefully. The regulatory landscape that made compounded GLP-1 medications legal has fundamentally changed, the enforcement clock is running, and some of the decisions patients are making right now in response to that change are genuinely dangerous.

I want to be precise about what’s happening, what it means for you as a California patient, and what your actual options are — because there’s a lot of confusion, a fair amount of misinformation, and real harm happening to patients who are either being misled by vendors trying to stay in the market or making desperate decisions on their own.

---

How Compounded GLP-1s Became Legal in the First Place

To understand why the ban is happening, you need to understand why compounding was ever permitted.

Under the Federal Food, Drug, and Cosmetic Act, FDA-approved drugs are generally protected from compounding — the law prohibits pharmacies from producing “essentially a copy” of an approved drug. This protection exists to prevent an end-run around the FDA’s drug approval process, which requires rigorous demonstration of safety, efficacy, and manufacturing quality.

There is, however, a specific exception: when an FDA-approved drug is on the official drug shortage list, compounding pharmacies — both 503A patient-specific pharmacies and 503B outsourcing facilities — may legally compound that drug, even if it’s essentially a copy of the approved product. The shortage exception exists because patient access is a legitimate competing interest when a drug is genuinely unavailable.

Semaglutide entered the FDA drug shortage list in 2022. With Ozempic and Wegovy in sustained shortage and patient demand vastly outpacing supply, compounding pharmacies began producing semaglutide at scale. Hundreds of thousands of patients — many of whom genuinely couldn’t access branded medication — were able to get treatment. This was, at the time, legally sanctioned and clinically defensible.

That period is over.

---

The Regulatory Timeline: What Has Changed

The sequence of events matters because patients in the middle of treatment need to understand where the law currently stands, not where it stood 18 months ago.

February 2025: The FDA declared the semaglutide injection shortage officially resolved. This is the pivotal event. Once a drug is removed from the shortage list, the legal basis for compounding “essentially a copy” of that drug collapses. The shortage exception no longer applies.

May 22, 2025: The deadline after which 503B outsourcing facilities — the large-scale commercial compounders that supply most telehealth platforms — may no longer legally compound semaglutide injection products. 503A pharmacies (the traditional patient-specific compounding pharmacies) lost their ability to compound semaglutide even earlier, as soon as the shortage was resolved.

2025–2026: The FDA has issued more than 50 warning letters to compounding pharmacies and telehealth companies still producing or distributing compounded semaglutide after these deadlines. This is not a regulatory suggestion. Warning letters are a formal enforcement step that precedes injunctions, seizures, and criminal referrals.

April 30, 2026: The FDA published a proposed rule to formally exclude semaglutide, tirzepatide, and liraglutide from the 503B bulk drug substances list — the list that defines which drugs outsourcing facilities are permitted to compound. A public comment period is open through June 29, 2026.

Clinical Callout: The proposed rule targeting tirzepatide is significant. While semaglutide enforcement has been active since early 2025, tirzepatide’s status has been more ambiguous. The April 2026 proposal signals that the FDA intends to apply the same framework to the entire GLP-1 class. If you’re on compounded tirzepatide, the regulatory trajectory is the same — just slightly behind semaglutide on the timeline.

Early 2026: Major telehealth platforms that had built substantial businesses around compounded GLP-1 medications have fully exited the market. Hims & Hers and Ro — two of the largest — discontinued compounded semaglutide programs entirely. Some platforms are attempting to pivot to alternative compounds (discussed below) or branded products.

---

The California Layer

California adds a state-level compliance dimension on top of federal FDA regulations, and it matters.

The California State Board of Pharmacy has its own oversight authority over compounding pharmacies operating in California or shipping into the state. California law is generally aligned with federal compounding standards but independently enforced. A pharmacy that is violating FDA rules is almost certainly violating California Board of Pharmacy regulations as well, and California enforcement can operate independently of — and sometimes faster than — federal action.

Practically speaking, this means:

• A California-licensed pharmacy producing compounded semaglutide after the shortage resolution is potentially facing both federal FDA enforcement and California Board of Pharmacy disciplinary action simultaneously.
• California patients receiving compounded semaglutide from out-of-state pharmacies (a common model with telehealth platforms) may be receiving product from pharmacies operating outside of California oversight — which means less recourse if something goes wrong.
• California prescribers who are facilitating access to non-compliant compounded GLP-1 products face their own professional liability exposure.

If your compounding pharmacy is still shipping you semaglutide injections today, you should be asking hard questions about their compliance posture — and taking their answers with skepticism.

---

What Vendors Are Doing to Stay in the Market

Not all vendors have exited cleanly. Some are attempting legal workarounds that range from genuinely legitimate to clearly problematic.

Semaglutide Salts and “Peptide” Formulations

Some compounders are marketing products as “semaglutide sodium” or “semaglutide acetate” rather than semaglutide itself, arguing these are chemically distinct compounds not covered by the FDA’s shortage resolution for semaglutide injection. The FDA has rejected this argument explicitly, issuing guidance that semaglutide salts and base forms are the same active ingredient and are subject to the same restrictions. Vendors marketing semaglutide in this way are, in the FDA’s current regulatory view, non-compliant.

”Research Use Only” and Peptide Companies

Some patients are encountering products labeled “for research use only” or sold through peptide research companies that are not licensed pharmacies. These products are not pharmaceutical grade, are not subject to any of the quality controls that govern compounding pharmacies, and have been the source of documented contamination and mislabeling events. The FDA has explicitly warned against these products. This is not a gray area.

Oral Formulations

A small number of 503A pharmacies are exploring oral compounded semaglutide formulations, arguing that the shortage resolution applied specifically to the injectable form. This is a genuinely contested legal space, but the FDA’s posture has been that the active ingredient is what matters, not the route of administration. Expect enforcement here as well.

Clinical Callout: The FDA identified counterfeit semaglutide in the U.S. drug supply as early as 2024 — before the crackdown intensified. The counterfeit products included vials with incorrect labeling, wrong concentrations, and in some cases no active ingredient. As patients are pushed toward non-traditional sources by the shutdown of legitimate compounders, the counterfeit and contamination risk increases substantially. If a source is not a state-licensed pharmacy with a valid prescription requirement, it is not safe.

---

The Patient Reality: What This Means If You’re Mid-Treatment

The people most affected by this crackdown are not bad actors — they’re patients who found an affordable path to a medication they needed, achieved real clinical results, and are now watching that access disappear mid-treatment.

The concerns I hear most from patients:

“I can’t afford branded Wegovy or Zepbound.” This is the most legitimate concern and the most solvable with the right support. Novo Nordisk and Eli Lilly both have patient assistance programs. The Novo Nordisk Patient Assistance Program covers Wegovy at no cost for qualifying patients. Manufacturer savings cards can reduce out-of-pocket cost to $0/month for commercially insured patients in many states, including California. The path to affordable branded medication exists — it requires navigation, and it’s easier with a clinician who does this regularly.

“My telehealth platform told me their product is still legal.” Treat this claim with skepticism proportional to the financial incentive behind it. Some platforms are operating in genuine good faith in a contested legal space. Others are selling non-compliant product and using legal ambiguity as marketing language. Ask specifically: is this a 503A or 503B compounded product? When was it produced? What is the pharmacy’s name and license number? If you can’t get clear answers to those questions, that is your answer.

“I’ve been on this for eight months and it’s working — I don’t want to stop.” This is completely valid, and stopping is not the recommendation. The recommendation is transition — from compounded to branded. Branded semaglutide (Wegovy) and branded tirzepatide (Zepbound) are the same molecules at the same or higher doses. Clinical continuity is achievable. What you should not do is interrupt treatment by going to an unverified source.

---

Your Actual Options Right Now

1. Branded Wegovy (Semaglutide Injection)

Now widely available. The shortage that drove the compounding market has genuinely resolved. Covered by an increasing number of insurance plans, particularly after the SELECT cardiovascular outcomes data. Patient assistance and savings programs available. Dose range goes up to 2.4 mg/week.

2. Zepbound (Tirzepatide)

Available and covered by a growing number of insurance plans. For most patients whose primary goal is weight loss without established cardiovascular disease, tirzepatide’s superior efficacy data make it the leading choice among available branded options. Eli Lilly’s savings card program has been competitive.

3. Metformin and Other Metabolic Agents

For patients who absolutely cannot access GLP-1 therapy financially, this is not the moment to go without treatment. Metformin is generically available for under $10/month, has meaningful effects on insulin resistance and modest effects on weight, and is appropriate as a bridge or adjunct while access to GLP-1 therapy is being sorted out.

---

A Word on International and Gray-Market Sources

I want to be direct about this because I know it’s what some patients are considering.

Semaglutide is approved and available in Canada, the UK, and much of Europe. Some patients are exploring medical tourism or gray-market importation. I understand the appeal when cost is the barrier. But there are real risks that are not adequately appreciated in online forums:

Importation of prescription drugs for personal use is technically illegal under U.S. federal law, even from legitimate foreign pharmacies, with narrow FDA enforcement discretion for small personal-use quantities. The risk of receiving counterfeit product — which has been documented even in domestic licensed compounding channels — is significantly higher with unverified international sources. And if something goes wrong, you have essentially no recourse.

The counterfeit problem is real enough that the FDA issued a specific safety communication in 2024 documenting counterfeit Ozempic in the domestic supply chain. I take that seriously. You should too.

---

The Pharmacist’s Bottom Line

The goal is not to scare patients off treatment. The goal is to help patients stay on effective, safe treatment through a regulatory transition that has created real disruption. Compounded GLP-1 medications served a legitimate function. That window has closed. The enforcement environment is serious and getting more serious. And the alternatives — branded medications with proper savings program navigation — are more accessible than the panic online would suggest.

If you are currently on compounded semaglutide or tirzepatide and haven’t started a transition conversation, start one now. Not after the next refill. Now.